

Table S1. Fasting plasma glucose, post prandial plasma glucose and blood pressure.

Study	FPG (Change from baseline) mmol/L	p value (between groups)	PPG (Change from baseline) mmol/L	p value (between groups)	SBP (Change from baseline) mm Hg	p value (between groups)	DBP (Change from baseline) mm Hg	p value (between groups)
EXENATIDE								
Apovian 2010[43]	Exe: -2.01 SD2.74 P: -0.94 SD2.77	p=0.0015	6-point SMBG profile: reduced in both groups	Not given	Exe: -9.44 SD13.72 P: -1.97 SD13.86	p<0.001	Exe: -2.22 SD9.8 P: +0.47 SD9.8	p=0.04
Bergental 2009[28]	Exe: -1.19 SD3.67 BIAsp BID: -3.48 SD3.56 BIAsp QD: -2.91 SD0.32	Exe vs. BIAsp BID: p<0.0001 Exe vs. BIAsp QD: p=0.0002	8-point glucose profile: significantly greater reduction at all points with BIAsp BID compared to exenatide; significantly greater reduction at all points except 2 hr after lunch and breakfast with BIAsp QD.	Not given	Not given	Not given	Not given	Not given
Bergental 2010[37]	Exe QW: -1.8 SD2.9 Sita: -0.9 SD2.62 Pio: -1.5 SD2.62	Exe QW vs. sita: p=0.0038 Exe QW vs. pio: p=NS	6-point SMBG profile: reduction with exenatide significantly greater than with sitagliptin but not pioglitazone	Exe QW vs. sita: p<0.05 Exe QW vs. pio: p=NS	Not given	Exe QW vs. sita: p=0.0055 Exe QW vs. pio: p=NS	The paper says ' <i>change in DBP at week 26 did not differ significantly between groups</i> '.	Not given
Bunck 2009[29]	Exe: -1.6 SD1.8 Glar: -2.9 SD2.3	p<0.001	7-point SMBG profile: significantly greater reductions in postprandial glucose excursions in exenatide-treated patients than insulin-treated patients	Not given	Not given	Not given	Not given	Not given
Davies 2009[30]	Exe: -2.29 SD2.64 Glar: -3.41 SD2.85	p<0.001	Not given	Not given	Exe: -2.9 SD12.98 Glar: +0.7 SD12.81	p=0.034	Exe: -0.5 SD7.57 Glar: +0.9 SD7.47	p=NS
Davis 2007[31]	Not given	Not given	5-point SMBG profile: significantly better post-prandial control with exenatide after breakfast than insulin; no consistent differences for the other time points	p<0.05	Not given	Not given	Not given	Not given
DeFronzo 2005[42]	Exe: -0.6 SD2.13 P: +0.8 SD2.13		Meal tolerance test: Exe: 7.2 SD3.2 mmol/L P: 12.8 SD4.5	p<0.05	Not given	Not given	Not given	Not given
DeFronzo 2010[22]	Exe: -1.46 SD1.68 Rosi: -1.80 SD1.68	p=NS	Standard meal tolerance test: AUC for glucose showed significant decrease in all groups	p=0.065	Not given	Not given	Not given	Not given
Derosa 2010[27]	Exe: -1.50 Glib: -1.78	p=NS	Exe: -1.67 Glib: -2.06	p=NS	Not given	Not given	Not given	Not given
Diamant 2010[34]	Exe QW: -2.1 SE0.2 Glar: -2.8 SE0.2	p=0.0001	8-point SMBG profile: both treatments reduced postprandial glucose at all eight time points. Glargine: lower glucose concentrations at 0300 h and before breakfast than exe; Exe: lower glucose concentrations after dinner than glargine. Exe caused greater reduction in postprandial glucose excursions than did insulin glargine after morning and evening meals.	p<0.0001 (for all eight time points)	Exe QW: -3 SE1.0 Glar: -1 SE1.0	Not given	Exe QW: -1 SE1.0 Glar: -1 SE1.0	Not given
Drucker 2008[41]	Exe: -1.4 SD2.4 Exe QW: -2.3 SD2.4	p<0.0001	Exe: -6.9 SD6.06 Exe QW: -5.3 SD6.08	p=0.0124	Exe: -3.4 SD13.34 Exe QW: -4.7 SD13.38		Exe: -1.7 SD8.49 Exe QW: -1.7 SD8.52	

Study	FPG (Change from baseline) mmol/L	p value (between groups)	PPG (Change from baseline) mmol/L	p value (between groups)	SBP (Change from baseline) mm Hg	p value (between groups)	DBP (Change from baseline) mm Hg	p value (between groups)
Gao 2009[45]	Exe: -1.3 SD2.73 P: -0.2 SD3.1		M-Value (SMBG variability) Exe: 19.7 SD27.53 P: 43.8 SD27.42; Mean daily glucose (SMBG profile) Exe: -2.3 SD3.06 P: -0.4 SD1.52	p<0.001	Not given	Not given	Not given	Not given
Gill 2010[26]	Not given	Not given	Not given	p=NS	Not given	p=NS	Not given	p=NS
Heine 2005[32]	Exe: -1.4 SD2.7 Glar: -2.9 SD2.9	p<0.001	7-points SMBG profile: mean daily monitored glucose levels were not different between treatment groups; but patients receiving glargine had lower BG at fasting, before meals, and at 3 am , but higher BG after morning and evening meals than patients receiving exenatide [i.e. BG levels were more level with exenatide]; AUC for PPG (SMBG profile): Exe: -8.9 Glar: -1; Meal test (positive incremental AUC at 4 hr): Exe: -8.6 Glar: -1.3	7-point: fasting, before meals, at 3 pm: p<0.001; morning and evening: p<0.001; AUC for PPG: p<0.001; Meal test: p<0.05	Not given	Not given	Not given	Not given
Kadowaki 2009[20]	Exe: -1.61 SD2.01 P: +0.33 SD1.71	p<0.001	Not given	Not given	Not given	Not given	Not given	Not given
Kendall 2005[21]	Exe: -0.6 SD3.1 P: +0.8 SD3.14		PPG geometric mean AUC 15 to 180 mins: Exe: -474 SE87 mmol/min/L P: -3 SE72 mmol/min/L; Standardized meal tolerance test: Exe: -2.9 SD11.80 P: +0.0 SD6.29	PPG geometric mean: p<0.001 Meal tolerance test: p<0.01	Not given	Not given	Not given	Not given
Nauck 2007[33]	Exe: -1.8 SD3.18 BIAsp BID: -1.7 SD3.15		7-point SMBG profile: Exe: significantly lower mean BG at 2 h post-breakfast and post-supper; BIAsp: significantly lower mean BG at pre-breakfast, pre-lunch and 3 am than exenatide	Post-breakfast and post-supper: p<0.001; Pre-breakfast, pre-lunch, 3pm: p<0.05	Exe: -5.0 SD15.0 BIAsp BID: +1.0 SD16.0		Exe: -2.0 SD10.0 BIAsp BID: +1.0 SD10.0	
Zinman 2007[67]	Exe: -1.59 SD2.42 P: +0.1 SD2.22		SMBG: Exe: significantly lower than baseline in exenatide group, P: no change compared to baseline	p<0.001	Not given	Not given	Not given	Not given

[illegible]

Study	FPG (Change from baseline) mmol/L	p value (between groups)	PPG (Change from baseline) mmol/L	p value (between groups)	SBP (Change from baseline) mm Hg	p value (between groups)	DBP (Change from baseline) mm Hg	p value (between groups)
Ratner 2010[25]	Tas 20 QW: -2.3 SD1.7 P: -0.6 SD1.7	p<0.0001	Not given	Not given	Not given	Not given	Not given	Not given
Nauck 2009[24]	Tas 10 QW: -2.5 Tas 20 QW: -2.5 Tas 20 every two weeks: -1.4 P: -0.78	Not given	plasma glucose 120 min after a mixed meal (% change from baseline): TAS 10 QW: -22% Tas 20 QW: -18% Tas 20 every two weeks: -5.5% P: -10.5%; Glucose AUC (from baseline): Tas 10 QW: -27.5% Tas 20 QW: -22.2% Tas 20 every two weeks: -9.2% P: -7.2%;	Not given	Not given	Not given	Not given	Not given

FPG: Fasting Plasma glucose; PPG: Postprandial glucose; SBP: Systolic blood pressure; DBP: Diastolic Blood pressure; BG: Blood glucose; Exe: Exenatide; Lir: Liraglutide; Albi: Albiglutide; Tas: Taspoglutide; BIAsp: Biphasic insulin aspart; Glar: Insulin glargine; Glib: Glibenclamide; Glim: Glimepiride; Sita: Sitagliptin; Rosi: Rosiglitazone; P: Placebo; BID: twice daily; QD: Once daily; QW: once weekly; SMBG: Self monitored blood glucose; AUC: Area under the curve; SD: Standard deviation; SE: Standard error; NS: Not significant; LEAD: Liraglutide Effect and Action in Diabetes